Hims & Hers reported second quarter 2026 revenue of $753.2 million, up 38% from a year earlier, and raised its full-year 2026 revenue guidance to $3.1 billion to $3.3 billion. The company swung to a net loss of $86.3 million from net income of $42.5 million in the prior-year quarter, and Adjusted EBITDA fell to $60.3 million from $82.2 million, so shareholders face higher revenue alongside lower profit.
Q2 2026 revenue was $753.2 million, up 38% year-over-year; subscribers reached 2,891 thousand, up 19%
Net loss was $86.3 million in Q2 2026 versus net income of $42.5 million in Q2 2025; gross margin fell to 64% from 76%
Adjusted EBITDA was $60.3 million versus $82.2 million a year earlier; Free Cash Flow was $(68.2) million
Full-year 2026 revenue guidance raised to $3.1 billion to $3.3 billion; Adjusted EBITDA guidance set at $275 million to $325 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Hims & Hers Health's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$2.35B
+59.0%
$0.51
-3.8%
5.5%
FY2024
$1.48B
+69.3%
$0.53
—
8.5%
FY2023
$872.00M
+65.5%
$-0.11
—
-2.7%
FY2022
$526.92M
+93.8%
$-0.32
—
-12.5%
FY2021
$271.88M
+82.8%
$-0.58
—
-39.6%
Frequently asked questions
When is Hims & Hers Health's next earnings date?
Hims & Hers Health (HIMS) is scheduled to report on Monday, November 09, 2026 after the market closes. Analysts expect EPS of $0.07.
What did Hims & Hers Health earn last quarter?
For the quarter ended Jun 2026, Hims & Hers Health reported diluted EPS of $-0.37 (-317.6% year over year) on revenue of $753.21M (+38.2%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.